Palvella Therapeutics Q3 FY24: revenue $0; diluted EPS −$2.19

Key figures from this report

These are the numbers Palvella Therapeutics reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$0No year-earlier figure tagged10-Q income statement, on EDGAR
2. Net income−$2.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
3. Diluted EPS−$2.19No year-earlier figure tagged10-Q income statement, on EDGAR
4. Cash and cash equivalents$19.4MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations$146KNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables